Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 21,119 Shares of Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 21,119 shares of the stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the transaction, the insider now owns 464,582 shares of the company’s stock, valued at $1,096,413.52. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Nuss also recently made the following trade(s):

• On Thursday, December 19th, John Nuss sold 13,161 shares of Ventyx Biosciences stock. The shares were sold at an average price of $2.26, for a total value of $29,743.86.

Ventyx Biosciences Price Performance

Shares of NASDAQ VTYX traded down $0.15 during midday trading on Monday, hitting $2.23. The company’s stock had a trading volume of 1,563,354 shares, compared to its average volume of 2,039,950. The business’s fifty day simple moving average is $2.29 and its two-hundred day simple moving average is $2.31. The firm has a market capitalization of $157.69 million, a price-to-earnings ratio of -0.94 and a beta of 0.48. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48.

Analyst Ratings Changes

Several analysts recently issued reports on VTYX shares. HC Wainwright restated a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer restated an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after acquiring an additional 7,096 shares during the last quarter. State Street Corp increased its position in shares of Ventyx Biosciences by 0.8% in the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after purchasing an additional 9,783 shares during the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at $26,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Ventyx Biosciences by 3.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock worth $1,058,000 after purchasing an additional 17,898 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.